Iris Biotech GmbH

Iris Biotech GmbH is a German biotechnology company established in 2001, with a focus on enabling peptide innovation. Over the years, the company has expanded its portfolio to encompass a unique range of standard reagents and unconventional building blocks, supported by custom synthesis services. Its commitment lies in providing essential support to its clientele, offering expertise, cutting-edge products, necessary analytics, and documentation to facilitate projects across various scales, from research to commercial production. The company's offerings cater to diverse segments within the biotechnology field. In the realm of drug discovery, Iris Biotech presents an array of critical components such as protected amino acids, coupling reagents, linkers, resins, natural and unusual amino acids, derivatives, fatty acid derivatives, and myriad other building blocks and resins. For drug delivery, the company boasts an extensive portfolio of PEGylation reagents, catering to a broad spectrum of requirements, including short, monodisperse hydrophilic linkers to long, polydisperse derivatives, alongside novel polymers with improved biodegradability. The company's innovative Linkerology section offers PROTAC building blocks, functionalized linkers, and fullerenes, adding distinct value to various research applications, from antioxidants to drug delivery. In its latest foray, Iris Biotech has ventured into the life sciences domain, introducing inhibitors, metabolites, substrates, fluorescent dyes, and natural products with biological and pharmaceutical significance, in addition to offering carbohydrates and Amadori and Maillard reaction products. Presently, there is no available information regarding the company's last investment and associated investors. However, considering its expansive and innovative product portfolio across critical domains in biotechnology, Iris Biotech GmbH presents itself as a compelling entity in the biotechnology sector, with potential for further growth, and potentially piquing the interest of venture capital firms looking to invest in cutting-edge biotech solutions.